STMN1 and prostate adenocarcinoma: Although there was no significant difference in overall survival rates between high and low STMN1 expression group in TCGA-PRAD dataset (p = 0.41, Fig. 2G), patients with high STMN1 expression exhibited a significantly lower disease-free survival probability (p < 0.01, Fig. 2F).